Nationally Ranked Investors Rights Firm Holzer and Holzer LLC Announces Investigation of KalVista (KALV)

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws. This follows the termination of its KOMPLETE phase 2 clinical trial for KVD824 on October 4, 2022, due to elevated liver enzymes observed in all treatment groups. This announcement resulted in a drop in the company's stock price. Investors who incurred losses on their KalVista stock are encouraged to contact Holzer & Holzer for legal advice regarding their rights.

Positive

• None.

Negative

• Termination of KOMPLETE phase 2 clinical trial for KVD824 due to liver enzyme elevations.
• Drop in stock price following the announcement of trial termination.

ATLANTA, GA / ACCESSWIRE / October 6, 2022 / Holzer & Holzer, LLC is investigating whether KalVista Pharmaceuticals, Inc. ("KalVista" or the "Company") (NASDAQ:KALV) complied with federal securities laws. On October 4, 2022, the Company announced it had terminated its KOMPLETE phase 2 clinical trial for KVD824 due to the observation of liver enzyme elevations in all trial treatment groups. After this announcement, the Company's stock price dropped.

If you purchased KalVista stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/kalvista to discuss your legal rights. 

Holzer & Holzer, LLC, a Top 50 securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT: 
Corey Holzer, Esq. 
(888) 508-6832 (toll-free) 
cholzer@holzerlaw.com

SOURCE: Holzer & Holzer

View source version on accesswire.com:
https://www.accesswire.com/719414/Nationally-Ranked-Investors-Rights-Firm-Holzer-and-Holzer-LLC-Announces-Investigation-of-KalVista-KALV

FAQ

What led to the investigation of KalVista Pharmaceuticals (KALV)?

The investigation stems from the company's announcement on October 4, 2022, regarding the termination of its KOMPLETE phase 2 clinical trial due to liver enzyme elevations.

What was the impact of the trial termination on KalVista's stock price?

Following the announcement of the KOMPLETE trial's termination, KalVista's stock price experienced a decline.

Who should I contact if I suffered losses from investing in KalVista (KALV)?

Investors who suffered losses can contact Holzer & Holzer, LLC for legal rights discussions.

What is the purpose of Holzer & Holzer's investigation into KalVista?

Holzer & Holzer is investigating potential compliance issues with federal securities laws following the company's trial termination announcement.